Literature DB >> 17970888

Mycophenolate mofetil.

Jeffrey Zwerner1, David Fiorentino.   

Abstract

Mycophenolate mofetil (MMF) is a relatively new systemic immunosuppressive agent whose use is rapidly increasing within the field of dermatologic. Originally used in the 1970s for the treatment of psoriasis, MMF has demonstrated efficacy in multiple types of inflammatory skin diseases. Although the safety data within the dermatologic literature is sparse, MMF's extensive use within the field of organ transplantation has demonstrated a favorable safety profile. MMF's lack of hepatic or renal toxicity is a significant advantage over immunosuppressive medications currently used in dermatology and make MMF an attractive candidate for multidrug regimens. In this review the present authors discuss the pharmacology, mechanisms of action, side effects and current uses of MMF reported within the dermatologic literature. The present authors also provide practical information regarding the use of the MMF culled from the literature as well as from the present authors' own clinical experience with the medication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17970888     DOI: 10.1111/j.1529-8019.2007.00136.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  19 in total

1.  Mycophenolate mofetil for interstitial lung disease in dermatomyositis.

Authors:  Pamela A Morganroth; Mary Elizabeth Kreider; Victoria P Werth
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-10       Impact factor: 4.794

2.  Wireless capsule endoscopy as a tool in diagnosing autoimmune enteropathy.

Authors:  Eva-Marie Gram-Kampmann; Søren T Lillevang; Sönke Detlefsen; Stig Borbjerg Laursen
Journal:  BMJ Case Rep       Date:  2015-07-06

3.  Mycophenolate mofetil in juvenile dermatomyositis: a case series.

Authors:  Rawane Dagher; Marine Desjonquères; Agnès Duquesne; Pierre Quartier; Brigitte Bader-Meunier; Michel Fischbach; Vincent Guiguonis; Georges Picherot; Rolando Cimaz
Journal:  Rheumatol Int       Date:  2010-12-09       Impact factor: 2.631

4.  Regulation of ribosomal RNA synthesis in T cells: requirement for GTP and Ebp1.

Authors:  Le Xuan Truong Nguyen; Yunqin Lee; Lenore Urbani; Paul J Utz; Anne W Hamburger; John B Sunwoo; Beverly S Mitchell
Journal:  Blood       Date:  2015-02-17       Impact factor: 22.113

5.  IgG4-related inflammatory pseudotumor of the central nervous system responsive to mycophenolate mofetil.

Authors:  Heather E Moss; Luis J Mejico; Gustavo de la Roza; Thomas M Coyne; Steven L Galetta; Grant T Liu
Journal:  J Neurol Sci       Date:  2012-04-28       Impact factor: 3.181

6.  Chromosomal aberrations in UVB-induced tumors of immunosuppressed mice.

Authors:  Amy M Dworkin; Kathleen L Tober; F Jason Duncan; Lianbo Yu; Anne M VanBuskirk; Tatiana M Oberyszyn; Amanda Ewart Toland
Journal:  Genes Chromosomes Cancer       Date:  2009-06       Impact factor: 5.006

7.  Granulomatous disease in common variable immunodeficiency.

Authors:  Omür Ardeniz; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2009-08-28       Impact factor: 3.969

8.  Checklists for safe prescribing in oral medicine clinics.

Authors:  M K Shephard; C Venda Nova; P Thakrar; T Hodgson
Journal:  Br Dent J       Date:  2017-10-27       Impact factor: 1.626

9.  New insights into neuromyelitis optica.

Authors:  Woojun Kim; Su-Hyun Kim; Ho Jin Kim
Journal:  J Clin Neurol       Date:  2011-09-29       Impact factor: 3.077

10.  Identifying disease-specific genes based on their topological significance in protein networks.

Authors:  Zoltán Dezso; Yuri Nikolsky; Tatiana Nikolskaya; Jeremy Miller; David Cherba; Craig Webb; Andrej Bugrim
Journal:  BMC Syst Biol       Date:  2009-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.